British Society for Rheumatology

Rheumatoid Arthritis Register

Recruiting to BSRBR-RA

Version 9: 01/08/2018

All registrations, both for participants new to the study and those who are already in the study but are being re-registered to a new cohort, will count towards UK CRN accrual data.

UK CRN ID: 7302.

Criteria for registration:

Diagnosis of Rheumatoid Arthritis → **Age 16 years and over** → **Starting treatment with biologic, biosimilar, or other advanced targeted therapy.**

- **Patients who are new to the study:** Registration documents must be received at the study offices within 6 months of therapy start date.
- **Patients already registered who are switching to a new eligible therapy:** Re-registration paperwork must be received at the study offices as soon as possible, but within 24 months of the switch at the very latest.

Currently accepting registrations for:

Actemra/RoActemra (tocilizumab)
Benepali (etanercept)
Cimzia (certolizumab)
Enbrel* (etanercept)
Erelzi (etanercept)
Flixabi (infliximab)
Humira* (adalimumab)
Inflectra (infliximab)
Kevzara (sarilumab)
Olumiant (baricitinib)
Remicade* (infliximab)
Remsima (infliximab)
Rixathon (rituximab)
Xeljanz (tofacitinib)

* Registrations for Humira, Enbrel and Remicade must be for biologic/biosimilar-naïve patients. Registrations for all other therapies do not have this requirement.

Registration forms available at www.bsrbr.org

Have a question? Please contact us! Tel: 0161 275 1652/7390
Email: biologics.register@manchester.ac.uk Twitter: @BSRBR_RA